{ "story_id": "4fc8040dec1125a885e1701d1fe0df8f", "desk": "drm3", "revision": 1, "published_at": "2026-09-02T10:16:22.000Z", "content_hash": "afc7786c4e1a8501d47c23cae73b724370a03489d928697b79d269e1795bed64", "hash_basis": "sha256 over `headline\\ndek\\nprose`, plus `\\n` + the canonical citations JSON when any source is placed, plus `\\n#blog` for blogs", "basis": { "headline": "Seoul Court Approves Homeplus Rehabilitation Plan", "dek": "A Seoul court approved a rehabilitation plan for discount chain Homeplus after creditors voted in favor.", "prose": "A Seoul court approved a rehabilitation plan for Homeplus Co. on Wednesday, Sept. 2, 2026, after creditors and shareholders voted in favor of the proposal. [^1]\n\nA Seoul court approved a corporate rehabilitation plan for Homeplus Co. on Wednesday, allowing the discount store chain to take the first step to revive its operation. [^2]\n\nBeagle Labs, a digital therapeutic device (DTx) specialist and subsidiary of Xperix, announced on September 2, 2026, that it has applied to the Ministry of Food and Drug Safety (MFDS) for approval of its clinical trial plan for the sarcopenia DTx DEX-2. [^3]\n\nMBK Partners Vice Chairman Kim Kwang-il stated that the key to the rehabilitation plan is securing profitability by scaling down the business to focus on profitable stores. [^4]\n\nThe plan involves immediately selling some stores to use the proceeds primarily to repay creditors. [^5]\n\nBeagle Labs developed the DEX-2 prototype with support from the Ministry of Trade, Industry and Energy's Biotechnology Industry Development Project, in collaboration with a research team from Bundang Seoul National University Hospital led by Professor Kim Kwang-il and Professors Lim Jae-young and Beom Jae-won. [^6]\n\nThis application marks the company's formal entry into the clinical trial and licensing process for the device, with plans to commence formal clinical trials upon MFDS approval and pursue product licensing based on acquired clinical data. [^7]\n\nBeagle Labs is jointly developing a digital fusion drug, DEX-1-OB, combining GLP-1 obesity new drug efglenatide with Hanmi Pharmaceutical, while conducting a pilot study to compare weight loss and muscle preservation effects when used alongside the drug versus drug monotherapy. [^8]", "cited": "[{\"statement\":\"A Seoul court approved a rehabilitation plan for Homeplus Co. on Wednesday, Sept. 2, 2026, after creditors and shareholders voted in favor of the proposal.\",\"source\":\"Yonhap News Agency\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-02T09:38:24.000Z\",\"publisher_count\":1,\"sources\":[\"Yonhap News Agency\"]},{\"statement\":\"A Seoul court approved a corporate rehabilitation plan for Homeplus Co. on Wednesday, allowing the discount store chain to take the first step to revive its operation.\",\"source\":\"Yonhap News Agency\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-02T10:16:22.000Z\",\"publisher_count\":1,\"sources\":[\"Yonhap News Agency\"]},{\"statement\":\"Beagle Labs, a digital therapeutic device (DTx) specialist and subsidiary of Xperix, announced on September 2, 2026, that it has applied to the Ministry of Food and Drug Safety (MFDS) for approval of its clinical trial plan for the sarcopenia DTx DEX-2.\",\"source\":\"매일경제\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-02T01:13:27.000Z\",\"publisher_count\":1,\"sources\":[\"매일경제\"]},{\"statement\":\"MBK Partners Vice Chairman Kim Kwang-il stated that the key to the rehabilitation plan is securing profitability by scaling down the business to focus on profitable stores.\",\"source\":\"Yonhap News Agency\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-02T09:38:24.000Z\",\"publisher_count\":1,\"sources\":[\"Yonhap News Agency\"]},{\"statement\":\"The plan involves immediately selling some stores to use the proceeds primarily to repay creditors.\",\"source\":\"Yonhap News Agency\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-02T09:38:24.000Z\",\"publisher_count\":1,\"sources\":[\"Yonhap News Agency\"]},{\"statement\":\"Beagle Labs developed the DEX-2 prototype with support from the Ministry of Trade, Industry and Energy's Biotechnology Industry Development Project, in collaboration with a research team from Bundang Seoul National University Hospital led by Professor Kim Kwang-il and Professors Lim Jae-young and Beom Jae-won.\",\"source\":\"매일경제\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-02T01:13:27.000Z\",\"publisher_count\":1,\"sources\":[\"매일경제\"]},{\"statement\":\"This application marks the company's formal entry into the clinical trial and licensing process for the device, with plans to commence formal clinical trials upon MFDS approval and pursue product licensing based on acquired clinical data.\",\"source\":\"매일경제\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-02T01:13:27.000Z\",\"publisher_count\":1,\"sources\":[\"매일경제\"]},{\"statement\":\"Beagle Labs is jointly developing a digital fusion drug, DEX-1-OB, combining GLP-1 obesity new drug efglenatide with Hanmi Pharmaceutical, while conducting a pilot study to compare weight loss and muscle preservation effects when used alongside the drug versus drug monotherapy.\",\"source\":\"매일경제\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-02T01:13:27.000Z\",\"publisher_count\":1,\"sources\":[\"매일경제\"]}]", "kind": "news" }, "receipt_verify": "Ed25519 over the dot-joined string `slice_hash.cursor_from.cursor_to.view.view_version.row_count`; public_key and sig are base64url of the raw 32-byte key / 64-byte signature", "receipt": null, "receipt_note": "this revision predates receipt-keeping (before v0.37.0); the filed row lives in the record", "generation_chain": { "wire": { "stream": "fountain_news", "story_id": "92fd375cfbc0147c54c1ce8b72e2e24b", "thread_id": "b9c9d357cb71bed75e74ec65df983a0b", "thread_label": "Kim Kwang-il", "novelty": "UPDATE", "content_hash": "6ac2abc86b2c7757215ee78c2fa6e8f5dd50a118629962f20ef47c1fa6295bdc", "last_published_at": "2026-09-02T10:16:22.000Z", "read_receipt": { "slice_hash": "6f69d013059537a87af2b87c922b212011d4fe7ee12036f9066de5c4cc30281c", "cursor_from": "eyJ0cyI6IjIwMjYtMDktMDJUMDk6NTM6MDUuMDAwMDAwWiIsImlkIjoiNTA2NzViODllMmUyZDU3ZGJhMzQzOWRiYTFlYmRkYmYiLCJ2IjoiMSJ9", "cursor_to": "eyJ0cyI6IjIwMjYtMDktMDJUMTE6MDA6MjIuMDAwMDAwWiIsImlkIjoiM2RkNTFiYjNlY2NkMTFkMzc0ZmJjN2UyNWU0OTBhOWYiLCJ2IjoiMSJ9", "view": "v_fountain_news", "view_version": "1", "row_count": 100, "window_days": 3, "bytes_scanned": 12017721, "credits": 8, "price_per_100_rows": 8, "sig": "y-CC-1scxAEM_nQQodB8JAFq-dwPb14ApmlmnG93xGLLF_uL8rplYgVGN6oy6mZzw1MUve5kLVLnYlxMxRVBDA", "public_key": "bMUigy8O0jOnBxQ4Sc-5lwhIZ8LQVAhxMbR7qESVuUE", "signer_path": "lakehouse/data-extract/v1", "alg": "Ed25519", "signed": true } }, "written_at": "2026-09-02T22:46:20.469Z" }, "cited_facts": [ { "statement": "A Seoul court approved a rehabilitation plan for Homeplus Co. on Wednesday, Sept. 2, 2026, after creditors and shareholders voted in favor of the proposal.", "source": "Yonhap News Agency", "instrument": "News", "claim_key": null, "published_at": "2026-09-02T09:38:24.000Z", "publisher_count": 1, "sources": [ "Yonhap News Agency" ] }, { "statement": "A Seoul court approved a corporate rehabilitation plan for Homeplus Co. on Wednesday, allowing the discount store chain to take the first step to revive its operation.", "source": "Yonhap News Agency", "instrument": "News", "claim_key": null, "published_at": "2026-09-02T10:16:22.000Z", "publisher_count": 1, "sources": [ "Yonhap News Agency" ] }, { "statement": "Beagle Labs, a digital therapeutic device (DTx) specialist and subsidiary of Xperix, announced on September 2, 2026, that it has applied to the Ministry of Food and Drug Safety (MFDS) for approval of its clinical trial plan for the sarcopenia DTx DEX-2.", "source": "매일경제", "instrument": "News", "claim_key": null, "published_at": "2026-09-02T01:13:27.000Z", "publisher_count": 1, "sources": [ "매일경제" ] }, { "statement": "MBK Partners Vice Chairman Kim Kwang-il stated that the key to the rehabilitation plan is securing profitability by scaling down the business to focus on profitable stores.", "source": "Yonhap News Agency", "instrument": "News", "claim_key": null, "published_at": "2026-09-02T09:38:24.000Z", "publisher_count": 1, "sources": [ "Yonhap News Agency" ] }, { "statement": "The plan involves immediately selling some stores to use the proceeds primarily to repay creditors.", "source": "Yonhap News Agency", "instrument": "News", "claim_key": null, "published_at": "2026-09-02T09:38:24.000Z", "publisher_count": 1, "sources": [ "Yonhap News Agency" ] }, { "statement": "Beagle Labs developed the DEX-2 prototype with support from the Ministry of Trade, Industry and Energy's Biotechnology Industry Development Project, in collaboration with a research team from Bundang Seoul National University Hospital led by Professor Kim Kwang-il and Professors Lim Jae-young and Beom Jae-won.", "source": "매일경제", "instrument": "News", "claim_key": null, "published_at": "2026-09-02T01:13:27.000Z", "publisher_count": 1, "sources": [ "매일경제" ] }, { "statement": "This application marks the company's formal entry into the clinical trial and licensing process for the device, with plans to commence formal clinical trials upon MFDS approval and pursue product licensing based on acquired clinical data.", "source": "매일경제", "instrument": "News", "claim_key": null, "published_at": "2026-09-02T01:13:27.000Z", "publisher_count": 1, "sources": [ "매일경제" ] }, { "statement": "Beagle Labs is jointly developing a digital fusion drug, DEX-1-OB, combining GLP-1 obesity new drug efglenatide with Hanmi Pharmaceutical, while conducting a pilot study to compare weight loss and muscle preservation effects when used alongside the drug versus drug monotherapy.", "source": "매일경제", "instrument": "News", "claim_key": null, "published_at": "2026-09-02T01:13:27.000Z", "publisher_count": 1, "sources": [ "매일경제" ] } ], "note": "A signature proves who filed this and that it has not changed since. It never makes a claim true." }